SAM-e (S-Adenosyl Methionine).

When SAM-e donates a methyl group it becomes homocysteine, and folate as 5-methyltetrahydrofolate supplies the methyl group that methionine synthase uses to recycle that homocysteine back to methionine. Pairing them supports the body's normal methyl-recycling loop.

Methionine synthase needs methylcobalamin to move the methyl group from folate onto homocysteine, regenerating the methionine that the body turns back into SAM-e. When B12 is short this remethylation step stalls, so the two act in the same pathway.

The homocysteine generated after SAM-e gives up its methyl group can also be routed down the transsulfuration pathway, where the vitamin B6-dependent enzyme cystathionine beta-synthase carries it toward cysteine. B6 supports this alternate route for handling homocysteine.

TMG feeds the betaine-homocysteine methyltransferase enzyme, an independent route that donates a methyl group to homocysteine and regenerates methionine alongside the folate and B12 pathway. It gives the body a second way to recycle the homocysteine that SAM-e use produces.

Methionine adenosyltransferase, the enzyme that builds SAMe from methionine and ATP, requires magnesium at its active site. Magnesium is also the counter-ion for the ATP that reaction consumes.

Methylenetetrahydrofolate reductase carries an FAD cofactor made from riboflavin, and that enzyme generates the methylfolate used to remethylate homocysteine back to methionine. Without riboflavin the folate arm of the cycle that regenerates SAMe runs slowly.

The final step of creatine synthesis uses SAMe as the methyl donor and accounts for a large share of whole-body methylation demand. Taking creatine directly lowers that draw and leaves more SAMe available for other methyl acceptors.

Glycine N-methyltransferase accepts surplus methyl groups from SAMe and passes them to glycine, forming sarcosine. That reaction is the body's buffer against an oversupplied methylation ratio, so glycine availability shapes how excess SAMe is handled.

Choline is oxidised to betaine, which donates a methyl group to homocysteine and regenerates methionine, the direct precursor of SAMe. The choline and folate methyl pools substitute for each other, so choline intake affects SAMe supply.

The PEMT pathway methylates phosphatidylethanolamine three times to make phosphatidylcholine, consuming three SAMe molecules per lipid. Supplying phosphatidylcholine directly lowers that demand on the methyl pool.

After SAMe donates its methyl group it becomes homocysteine, which can be routed down transsulfuration to cysteine and then glutathione. NAC feeds that same cysteine pool from the other end, supporting the outflow side of the cycle.

Glutathione is the end product of the transsulfuration branch that begins with the homocysteine left over after SAMe donates a methyl group. Adequate SAMe supports the flux into that branch through cystathionine beta-synthase.

Betaine-homocysteine methyltransferase and methionine synthase are both zinc-dependent, activating the thiol of homocysteine so a methyl group can be transferred. Zinc status therefore sets the rate at which methionine and then SAMe are regenerated.

SAMe raises methylation-dependent monoamine turnover and St John's wort slows monoamine reuptake, so the two push serotonergic signalling in the same direction. That overlap is a settled reason to stagger rather than stack them.

5-HTP supplies the immediate precursor for serotonin synthesis while SAMe supports the methylation steps in monoamine metabolism. Combining them raises serotonergic tone from two points on the same pathway.

Sulfur leaving the transsulfuration branch ends as sulfite, which sulfite oxidase converts to sulfate using a molybdenum cofactor. A heavier methylation and sulfur load makes that final step matter more.

5-methyltetrahydrofolate donates its methyl group to homocysteine through methionine synthase, remaking methionine, which is then adenosylated back to SAM. Without adequate folate in that active form the cycle stalls and homocysteine accumulates rather than being remethylated. This is core one-carbon biochemistry and needs no trial to state. It is the reason SAM-e products are commonly built alongside B vitamin cofactors.

Methionine adenosyltransferase condenses methionine with ATP to make S-adenosyl methionine, so dietary methionine supply sets the ceiling on endogenous SAM production. Supplementing SAM directly bypasses that step. The two are the substrate and the product of the same reaction. Extra methionine without adequate B vitamin cofactors raises homocysteine instead of methylation capacity.

After SAM donates its methyl group it becomes S-adenosyl homocysteine and then homocysteine, which can be diverted down transsulfuration to cystathionine and on to cysteine. SAM itself allosterically activates cystathionine beta-synthase, the gate on that route. Cysteine is then the rate-limiting input for glutathione synthesis. The connection is textbook and does not depend on any trial.

Excess selenide is methylated for excretion using SAM as the methyl donor, so selenium disposal draws on the same methyl pool. Selenium is also required for glutathione peroxidase, which sits downstream of the cysteine that transsulfuration produces. The two nutrients are connected at both ends of the pathway. This is mechanistic biochemistry rather than a measured combination effect.

Nicotinamide is cleared largely by N-methylation to N1-methylnicotinamide, a reaction that spends a methyl group from SAM. Large niacin or nicotinamide doses therefore draw on the methyl pool and can raise homocysteine, a documented pharmacological effect. Anyone combining high-dose niacin with methylation support should know the two are competing for the same currency. This is established pharmacology, not speculation.

Nicotinamide riboside raises the nicotinamide pool, and surplus nicotinamide is disposed of by SAM-dependent N-methylation. The methyl demand rises with the dose. It is why methyl donor status is discussed alongside NAD precursor supplementation. The direction is competition for methyl groups, not an effect on NAD itself.

Acetylserotonin O-methyltransferase transfers a methyl group from SAM to N-acetylserotonin to give melatonin, so the pineal step depends directly on the SAM pool. That is settled biochemistry regardless of whether oral SAM-e changes melatonin output. Supplemental melatonin bypasses the synthesis route entirely. The two connect at a defined enzymatic step, not at a clinical outcome.

Quercetin and related flavonols are extensively O-methylated by catechol O-methyltransferase during first-pass metabolism, and every methylation spends a SAM methyl group. High-dose polyphenol intake therefore draws on the methyl pool. It is a documented metabolic route for these compounds. The practical significance at ordinary supplement doses is not established.

Catechol-containing catechins including EGCG are methylated by COMT, which consumes SAM and also produces S-adenosyl homocysteine, itself an inhibitor of methyltransferases. Sustained high catechin intake is one of the recognised dietary draws on the methyl pool. This is enzymology rather than an outcome claim. It is worth noting on a label that combines the two.

Serine hydroxymethyltransferase transfers a carbon unit from serine to tetrahydrofolate, generating the methylene folate that is reduced to the methyl folate used to remake methionine. Serine is the main one-carbon donor in this cycle. That places it upstream of the whole SAM supply chain. The relationship is textbook.

Choline is oxidised to betaine, which remethylates homocysteine through betaine homocysteine methyltransferase, a folate-independent route back to methionine and therefore to SAM. CDP-choline delivers choline along with cytidine. It supports the same cycle from a different entry point than folate does. The connection is settled biochemistry.

Alpha-GPC is a choline donor, and part of the choline pool is oxidised to betaine, which hands a methyl group to homocysteine to regenerate methionine. That is the folate-independent half of remethylation. It links a choline supplement directly to the SAM cycle. Phosphatidylcholine synthesis in the other direction is itself a major SAM consumer.

Phosphatidylethanolamine N-methyltransferase uses three SAM molecules per phosphatidylcholine made, which is one of the largest single methyl demands in the liver, and inositol phospholipid handling sits in the same membrane pool. The link between an inositol supplement and SAM status is indirect. Read it as mechanistic context rather than a tested pairing. Nothing in the candidate set measures it.

The clearance route for surplus nicotinamide is SAM-dependent methylation, so high-dose B3 in any of its common forms is a methyl sink. This has been described as a driver of the homocysteine rise seen with pharmacological niacin dosing. It is worth stating on a formula that stacks both. The effect scales with dose.

Cysteine generated through transsulfuration can go to glutathione or on to taurine through cysteine dioxygenase, so the two endpoints share one upstream supply. Supplying taurine directly spares that cysteine for other uses. The relationship is a branch point in sulfur amino acid metabolism. It is a mechanistic connection, not a measured combination.